Arvest Bank Trust Division Sells 15,867 Shares of Johnson & Johnson $JNJ

Arvest Bank Trust Division cut its holdings in Johnson & Johnson (NYSE:JNJ) by 20.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 60,784 shares of the company’s stock after selling 15,867 shares during the quarter. Johnson & Johnson accounts for approximately 0.8% of Arvest Bank Trust Division’s holdings, making the stock its 29th largest position. Arvest Bank Trust Division’s holdings in Johnson & Johnson were worth $14,858,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Daner Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the first quarter worth approximately $311,000. First Citizens Bank & Trust Co. lifted its holdings in shares of Johnson & Johnson by 1.4% during the 1st quarter. First Citizens Bank & Trust Co. now owns 56,542 shares of the company’s stock valued at $13,821,000 after buying an additional 790 shares during the period. Alesco Advisors LLC An ESL Co lifted its holdings in shares of Johnson & Johnson by 10.2% during the 1st quarter. Alesco Advisors LLC An ESL Co now owns 5,942 shares of the company’s stock valued at $1,452,000 after buying an additional 551 shares during the period. CI Investments Inc. increased its position in Johnson & Johnson by 83.5% during the first quarter. CI Investments Inc. now owns 317,660 shares of the company’s stock valued at $77,649,000 after acquiring an additional 144,553 shares during the last quarter. Finally, First Trust Advisors LP boosted its position in Johnson & Johnson by 1.6% in the first quarter. First Trust Advisors LP now owns 2,108,927 shares of the company’s stock worth $515,506,000 after purchasing an additional 33,425 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the topic of several recent research reports. HSBC set a $290.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Monday, July 6th. Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Argus lifted their price objective on Johnson & Johnson from $240.00 to $275.00 and gave the company a “buy” rating in a research report on Thursday, April 16th. Stifel Nicolaus set a $260.00 price objective on Johnson & Johnson in a research note on Wednesday, July 15th. Finally, Wells Fargo & Company upped their price target on shares of Johnson & Johnson from $263.00 to $272.00 and gave the stock an “overweight” rating in a research report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $265.30.

Johnson & Johnson Trading Up 2.0%

JNJ opened at $255.71 on Thursday. Johnson & Johnson has a 12 month low of $164.23 and a 12 month high of $269.43. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. The stock has a 50-day moving average of $241.40 and a 200 day moving average of $235.76. The firm has a market cap of $615.56 billion, a P/E ratio of 29.63, a P/E/G ratio of 2.38 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.84 by $0.06. The business had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a return on equity of 32.86% and a net margin of 21.48%.The company’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same period last year, the company earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, research analysts forecast that Johnson & Johnson will post 11.68 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson’s payout ratio is 62.11%.

Insider Activity at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the sale, the executive vice president directly owned 114,288 shares in the company, valued at approximately $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The FDA approved J&J’s OTTAVA robotic surgery system, opening the door for Johnson & Johnson to compete in robotic soft-tissue surgery and potentially expand its medtech growth runway. Reuters article on OTTAVA approval
• Positive Sentiment: Investors are also encouraged by the prospect of a phased launch of OTTAVA with select customers, suggesting J&J is preparing a commercial rollout after securing clearance. Medical Device Network article on OTTAVA launch plans
• Positive Sentiment: J&J also continues to look like a defensive income stock, with a newly declared quarterly dividend reinforcing its appeal to dividend-focused investors. Yahoo Finance dividend article
• Neutral Sentiment: A federal judge cast doubt on roughly 69,000 talc-related cancer claims, but the court did not dismiss the litigation outright, so the legal overhang remains a mixed but potentially improving risk for J&J. Reuters talc litigation article

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.